TransMedics Q3 Revenue Rises 41% to $203 Million; Raises 2026 Guidance
TransMedics reported Q3 2026 revenue of $203.0M, up 41% YoY, and raised 2026 guidance to $764M-$774M. Net income was $17.1M, with adjusted EPS of $0.51. The company made progress in clinical trials and European operations, including FDA approvals and a new CFO appointment.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance raise provide fresh material for valuation models and may trigger short covering.
Market read
First‑report earnings and guidance lift for TMDX; likely short‑term price move.
What to watch
Potential regulatory delays in Europe and cash burn from trial expenses could offset revenue gains.
Background
TransMedics is a US‑listed medical‑device company focused on organ‑preservation technologies.
Ticker impact
TransMedics reported Q3 2026 revenue up 41% YoY to $203M and raised full‑year guidance to $764‑$774M.
likely upward pressure as investors price in higher revenue outlook
Revenue growth and higher guidance are fresh, material data for a micro‑cap biotech; market typically reacts positively to such upgrades.
Market effects
Positive signal for the organ‑transplant and medical‑device sector, may boost peers with similar pipelines.
Limited to US biotech investors; no broad regional effect.
Minimal global impact beyond niche biotech community.
Counterpoint
Guidance may be optimistic; execution risk on European tender and trial timelines could temper upside.
Key entities
- companyTransMedics Group, Inc.
Medical‑device firm reporting Q3 results.
- personFernando Araujo
New CFO appointed from GE HealthCare.
